-

A.forall Announces First US Launch with Coveted Competitive Generic Therapy (CGT) Exclusivity of Tromethamine Injection 18GM/500mL

WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--A.forall announced through its U.S. subsidiary, Milla Pharmaceuticals Inc., that it has received Abbreviated New Drug Application (ANDA) approval by the U.S. Food and Drug Administration (FDA) for a generic version of THAM Solution Tromethamine Injection 18GM/500mL marketed by Hospira Inc, a Pfizer company.

Tromethamine Injection is indicated for prevention and correction of metabolic acidosis.

This marks the 6th overall ANDA approval for A.forall and another instance where Competitive Generic Therapy (CGT) eligibility has been granted. Moreover, Milla Pharmaceuticals is commercializing Tromethamine Injection using their own label and their expanded US market presence, offering more direct access to customers and patients.

“As this product was previously reported in shortage in the U.S. for multiple years, the approval and launch of Tromethamine Injection reinforce our mission of making affordable medicines available to all, by continuing the expansion of high-quality generic injectables supply throughout and beyond the U.S. market,” commented Erik Lazarich, A.forall’s President of U.S. Operations.

Commercialization is currently underway, with a 180-day exclusivity as from launch.

Please see link for Full Prescribing Information.

About A.forall & Milla Pharmaceuticals

At A.forall, our mission is all about Making Affordable Medicines Available To All: we develop value-added generic pharmaceuticals, solve product shortages and fill unmet medical needs so that patients can continue their treatment.

At the same time, we are reducing costs to the healthcare system and increasing customer convenience for a more sustainable world.

Milla Pharmaceuticals Inc., the U.S. subsidiary of A.forall, is engaged in the development, licensing, acquisition, and commercialization of generic prescription drugs for the U.S. market, focusing on niche injectable and solution products for hospitals and clinics.

More info: About – A.forall & About - Milla Pharmaceuticals

Contacts

Erik Lazarich
Milla Pharmaceuticals Inc.
1310 Highway 96 E, Suite 104A
White Bear Lake, MN 55110-3618

+1 (952) 449-5154

erik.lazarich@aforallpharma.com

Industry:

Milla Pharmaceuticals

Release Versions
English

Contacts

Erik Lazarich
Milla Pharmaceuticals Inc.
1310 Highway 96 E, Suite 104A
White Bear Lake, MN 55110-3618

+1 (952) 449-5154

erik.lazarich@aforallpharma.com

Social Media Profiles
Milla Pharmaceuticals, an A.forall company
A.forall
More News From Milla Pharmaceuticals

A.forall expands US generics portfolio

ANDERLECHT, Belgium--(BUSINESS WIRE)--A.forall is pleased to announce the acquisition of four FDA-approved injectable generics and two late-stage pipeline assets from Provepharm's US portfolio. With this acquisition, A.forall considerably extends its marketed portfolio in the US, marking a significant expansion of its US footprint and a key milestone in the company’s sharpened focus on high-quality generics worldwide. Strengthening Essential Healthcare The acquired portfolio includes four well-...

A.forall Announces the Direct Commercialization of Sodium Acetate Injection 2mEq/mL

WHITE BEAR LAKE, Minn.--(BUSINESS WIRE)--Through its U.S. subsidiary, Milla Pharmaceuticals Inc., A.forall announced the direct commercialization and launch of Sodium Acetate Injection 2mEq/mL in 20mL, 50mL, and 100mL vials. Sodium Acetate Injection, USP is indicated as a source of sodium for addition to large volume intravenous fluids to prevent or correct hyponatremia in patients with restricted or no oral intake. It is also useful as an additive for preparing specific intravenous fluid formu...

A.forall Announces the Launch of Their Fifth Abbreviated New Drug Application (ANDA) and Second “First Cycle” FDA Approval

MINNETONKA, Minn.--(BUSINESS WIRE)--A.forall’s U.S. subsidiary Milla Pharmaceuticals Inc. announced the launch of the group’s generic version of Precedex®, Dexmedetomidine Hydrochloride Injection 200 mcg per 50 mL and 400 mcg per 100 mL in 0.9% sodium chloride in glass bottles by its partner Sagent Pharmaceuticals. Dexmedetomidine Hydrochloride Injection is indicated for sedation of initially intubated and mechanically ventilated patients during treatment in an intensive care setting. Dexmedeto...
Back to Newsroom